Summary: A large-scale theoretical, historical and statistical analysis of pharmaceutical regulation in the United States as it is carried out by the U.S. Food and Drug Administration (FDA). This project has been funded by the National Science Foundation (SES-0076452, for "Formal and Empirical Analyses of Bureaucratic Delay: The Case of FDA Drug Review") (2000-2003), the Robert Wood Johnson Foundation Scholars in Health Policy Program (1998-2000), a Robert Wood Johnson Foundation Investigator Award in Health Policy Research (2004-2006), the Edmund J. Safra Center for Ethics at Harvard University, the National Institutes of Health through Harvard Catalyst (grant 1UL1RR025758-01), and the PriceWaterhouse Coopers Endowment for the Business of Government.

None of these foundations or entities in any way endorses, or is otherwise responsible for, the contents of this Web site or Web page, or for any papers produced or claims found herein. Professor Carpenter neither seeks nor accepts research funding or any other form of compensation from the FDA, from private entities that may sponsor product applications to the FDA or that are otherwise regulated by the FDA, from patient advocacy groups or from consumer advocacy groups (e.g., Public Citizen). In addition, Professor Carpenter does not directly own stock or any other form of asset in any company regulated by the FDA. [A note about this policy.]